Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
Authors
Keywords
-
Journal
Scientific World Journal
Volume 2015, Issue -, Pages 1-6
Publisher
Hindawi Limited
Online
2015-02-16
DOI
10.1155/2015/317507
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
- (2014) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- The perils of clinical trials
- (2014) Richard E. Gilbert KIDNEY INTERNATIONAL
- Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
- (2014) Muralikrishna Gangadharan Komala et al. PLoS One
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
- (2013) J.-F. Yale et al. DIABETES OBESITY & METABOLISM
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- FDA rejects novel diabetes drug over safety fears
- (2012) Talha Khan Burki LANCET
- Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area
- (2012) Gabriel Coll-de-Tuero et al. BMC Nephrology
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
- (2012) Christine Clar et al. BMJ Open
- Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
- (2011) Scott C. Thomson et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
- (2011) Giovanni Musso et al. ANNALS OF MEDICINE
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
- (2011) David R. Whiting et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- Effect of kidney disease on glucose handling (including genetic defects)
- (2011) Joaquim Calado et al. KIDNEY INTERNATIONAL
- Biology of Human Sodium Glucose Transporters
- (2011) Ernest M. Wright et al. PHYSIOLOGICAL REVIEWS
- Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States
- (2010) Carol E. Koro et al. CLINICAL THERAPEUTICS
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
- (2010) V. Vallon et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion
- (2008) J. Calado et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More